摘要
目的:应用胰激肽原酶治疗2型糖尿病(T2DM)早期肾病患者,观察尿微量白蛋白及纤维蛋白原(FIB)、C反应蛋白(CRP)变化。方法:T2DM早期肾病患者(尿白蛋白排泄率UAER20～200μg.min-1)70例随机分为胰激肽原酶治疗组40例及非治疗组30例,测定血糖及血脂、UAER、CRP、FIB等。另选30例正常健康者作对照组。结果:血糖、TG、CRP、FIB、UAER在2组均有下降,治疗组与非治疗组比较有统计学意义(P<0.01)。HDL逐渐升高,2组有统计学意义(P<0.05)。结论:胰激肽原酶可在降低TG、CRP、FIB水平的同时,降低UAER水平,使用胰激肽原酶进行干预可有效减轻DN患者微量白蛋白尿。
OBJECTIVE Kallidianogenase can be availably used to decrease microalbuminuria in diabetic nephropathy patients. The aim of this study is to determine the change of urinary albumin excretion rate（UAER）, fibrinogen （FIB） and C-reactive protein（CRP） after kallidinagenase treatment in type 2 diabetic patients. METHODS 70 cases of early dibetic nephypothy group（UAER 20- 200μg·min^-1） were randomly divided into kallidianogenase treated groupe （40 patients） and without klallidianogenase treated group （30 patients）. The changes of glucose, plasma lipid, UAER, CRP, FIB et al were examined in all of the patients. Meanwhile, 30 healthy subjects were selected for the normal control（NC）. RESULTS The level of plasma glucose, TG, CRP, FIB, UAER decreased obviously in two groups, HDL is elevated gradually, which havd statistical difference between the kallidianogenase-treated group and without kallidianogenase treated group （P〈0. 01 or P〈0. 05）. CONCLUSION Kallidianogenase can decrease TG, and increase HDL efficiently. Besides, it can decrease the level of CRP and FIB, thus can decrease UAER. The using of Kallidianogenase in DN patients can lessen microalbuminuria.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2012年第8期628-630,共3页
Chinese Journal of Hospital Pharmacy
